Fig. 2

Fig. 2

Mutant Prkci^I316A has normal in vivo biological activity.

(A) Reconstruction of confocal Z-stack sections of embryonic hearts at 28–30 hpf. Transgenic Tg[cmlc2:GFP]^twu34 one-cell stage embryos were injected with prkci MO alone or together with mRNA encoding Prkci^WT or analog-sensitive mutant forms of Prkci. Whereas the wild-type heart elongates into a heart tube and towards the left during cardiac jogging, heart development arrests at the cone stage and the heart remains at the embryonic midline in prkci morphants. In functional rescue experiments, injection of prkciMO together with mRNA encoding HisMyc-Prkci^WT or Prkci^I316A rescues heart tube elongation. In comparison, the analog-sensitive mutant form Prkci^V300A fails to rescue heart tube formation in prkci morphants. Percentiles indicate the occurrence of the most common phenotype as depicted in the images and numbers show the total of embryos tested. White dotted line indicates the embryonic midline. L, left; R, right. (B) Membrane localization of endogenous Prkci detected with an anti-Prkci antibody and exogenous Prkci^WT or Prkci^I316A in zebrafish cardiomyocytes detected with an anti-Myc antibody. Images are confocal reconstructions of single Z-stack sections of embryonic hearts marked by the transgenic reporter Tg[cmlc2:GFP]^twu34 at 28–30 hpf. Expression of exogenous HisMyc-Prkci^WT or HisMyc-Prkci^I316A in cardiomyocytes reveals that both recombinant proteins localize to the cell membrane.